Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... memory device for computing may have just taken an ... New York led by chemist Stephen O,Brien have discovered ... properties. , Combining both properties is very exciting scientifically ... for the devices that might ultimately be designed, in ... a single material, however, has proved difficult until now. ...
(Date:9/18/2014)... 18, 2014 September 24 marks ASEA's ... ASEA is the manufacturer of the world's first and ... product, RENU28. , The Mexico City event features ... Botero, and ASEA Field Leader Shawn Catmull from Draper, ... in Atomic/Medical Physics from the University of Utah and ...
(Date:9/17/2014)... , Sept. 17, 2014 A ... accelerated partial breast irradiation (APBI) via interstitial brachytherapy ... with positive lymph nodes could be suitable to ... Oncology (ASTRO) guidelines place these patients in the ... at the 2014 ASTRO meeting, Beaumont Health System,s ...
(Date:9/17/2014)... N.C. , Sept. 17, 2014  The In ... topics that will be featured at the conference, which ... Center on December 3 and 4, 2014. Researchers, students, ... invited to hear the following: KEYNOTE ... San Diego Skaggs School of Pharmacy ...
Breaking Biology Technology:Oxides discovered by CCNY team could advance memory devices 2Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7
... are used in a wide variety of applications ... and aerospace applications. Thermal analysis is routinely used ... growing trend to use nanostructured materials has made ... an atomic force microscope-based technique called nanoscale thermal ...
... laboratory has found a way to turn common carbon ... with properties expected to prove useful in electronic, optical ... scientist Pulickel Ajayan, in collaboration with colleagues in China, ... one-step chemical process that is markedly simpler than established ...
... cell therapy manufacturing division, Progenitor Cell Therapy ("PCT"), ... NBS ) ("NeoStem" or the "Company"), announced today ... and regulatory services related to the development of ... injectable suspension of microencapsulated insulin-producing, pancreatic islet cells ...
Cached Biology Technology:Magnetic actuation enables nanoscale thermal analysis 2Graphene quantum dots: The next big small thing 2Graphene quantum dots: The next big small thing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 2Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 3Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing 4
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
Breaking Biology News(10 mins):Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Forest Service scientists have found that prescribed fires with the ... oak ecosystems. Forest Service researchers are helping land ... oak regeneration from acorns is a concern. "Acorns ... the most part protected from fire," says Cathryn Greenberg, Forest ...
... in JoVE , the Journal of Visualized ... spider silk from bacteria. The procedure presented in the ... standardizing a key step known as "post-spin." In this ... to increase fiber strength. These mechanical improvements produce uniform ...
... Waterlogged protein . . . Proteins, biological ... our bodies, are known to rely heavily on the ... remained unclear. In a paper published in Physical Review ... new evidence that suggests water is even more involved ...
Cached Biology News:Leaf litter and soil protect acorns from prescribed fire 2The future of biomaterial manufacturing: Spider silk production from bacteria 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2012 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2012 3
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... to ADAMTS16 ( Abpromise for ... Antigen: Synthetic peptide based on ... Note: the amino acid sequence is ... 170690 SWISS ...
... Immunogen: KLH-conjugated, synthetic ... in which [ Ac K] corresponds to ... Accession Number: NM_003493 ... ~17kDa Quality Assurance: ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: